Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
-
NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel
-
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
-
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
-
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
-
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
-
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
-
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
-
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
-
NurExone released a corporate update and reported financial results for the quarter ended September 30, 2023.